Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations

This publication has 18 references indexed in Scilit:

• Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases
  Current Pharmacogenomics, 2005
• Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding
  Nucleic Acids Research, 2005
• Defining the Basis for the Specificity of Aminoglycoside-rRNA Recognition: A Comparative Study of Drug Binding to the A Sites of Escherichia coli and Human rRNA
  Journal of Molecular Biology, 2005
• Molecular Insights into Aminoglycoside Action and Resistance
  Chemical Reviews, 2004
• Pharmacologic therapy for stop mutations: how much CFTR activity is enough?
  Current Opinion in Pulmonary Medicine, 2004
• Gentamicin-Induced Correction of CFTR Function in Patients with Cystic Fibrosis andCFTRStop Mutations
  New England Journal of Medicine, 2003
• Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics
  Nature, 2000
• Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system
  RNA, 2000
• Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs
  Nucleic Acids Research, 1994
• AMINOGLYCOSIDE ANTIBIOTICS. VII
  The Journal of Antibiotics, 1974